Mesoblast Limited Receives Clearance to Begin Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Diabetic Nephropathy

Published: Jun 26, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Melbourne, Australia; 26 June 2013 and New York, USA; 25 June 2013: Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has received approvals from Australian ethics committees to commence a Phase 2 trial evaluating a single intravenous infusion of its proprietary allogeneic or “off-the-shelf” adult Mesenchymal Precursor Cells (MPCs) in patients with type 2 diabetes and advanced kidney disease, or diabetic nephropathy.

Help employers find you! Check out all the jobs and post your resume.

Back to news